These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 22390693)
1. The mechanism of adjuvanticity of aluminium-containing formulas. Fierens K; Kool M Curr Pharm Des; 2012; 18(16):2305-13. PubMed ID: 22390693 [TBL] [Abstract][Full Text] [Related]
2. When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes. Exley C Vaccine; 2012 Mar; 30(12):2042. PubMed ID: 22041301 [No Abstract] [Full Text] [Related]
3. Alum adjuvant: some of the tricks of the oldest adjuvant. Kool M; Fierens K; Lambrecht BN J Med Microbiol; 2012 Jul; 61(Pt 7):927-934. PubMed ID: 22174375 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Berthold I; Pombo ML; Wagner L; Arciniega JL Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073 [TBL] [Abstract][Full Text] [Related]
5. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Calabro S; Tritto E; Pezzotti A; Taccone M; Muzzi A; Bertholet S; De Gregorio E; O'Hagan DT; Baudner B; Seubert A Vaccine; 2013 Jul; 31(33):3363-9. PubMed ID: 23684834 [TBL] [Abstract][Full Text] [Related]
6. The global impact of vaccines containing aluminium adjuvants. Clements CJ; Griffiths E Vaccine; 2002 May; 20 Suppl 3():S24-33. PubMed ID: 12184361 [TBL] [Abstract][Full Text] [Related]
7. Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations. Mold M; Shardlow E; Exley C Sci Rep; 2016 Aug; 6():31578. PubMed ID: 27515230 [TBL] [Abstract][Full Text] [Related]
8. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. al-Shakhshir RH; Regnier FE; White JL; Hem SL Vaccine; 1995 Jan; 13(1):41-4. PubMed ID: 7762276 [TBL] [Abstract][Full Text] [Related]
9. Alum adjuvanticity: unraveling a century old mystery. De Gregorio E; Tritto E; Rappuoli R Eur J Immunol; 2008 Aug; 38(8):2068-71. PubMed ID: 18651701 [TBL] [Abstract][Full Text] [Related]
10. Adjuvants--a balance between toxicity and adjuvanticity. Gupta RK; Relyveld EH; Lindblad EB; Bizzini B; Ben-Efraim S; Gupta CK Vaccine; 1993; 11(3):293-306. PubMed ID: 8447157 [TBL] [Abstract][Full Text] [Related]
11. Aluminium-based adjuvants should not be used as placebos in clinical trials. Exley C Vaccine; 2011 Nov; 29(50):9289. PubMed ID: 21871940 [No Abstract] [Full Text] [Related]
12. Dendritic Mesoporous Silica Nanoparticle Adjuvants Modified with Binuclear Aluminum Complex: Coordination Chemistry Dictates Adjuvanticity. Yang Y; Tang J; Song H; Yang Y; Gu Z; Fu J; Liu Y; Zhang M; Qiao ZA; Yu C Angew Chem Int Ed Engl; 2020 Oct; 59(44):19610-19617. PubMed ID: 32876984 [TBL] [Abstract][Full Text] [Related]
13. Predicting the adsorption of proteins by aluminium-containing adjuvants. Seeber SJ; White JL; Hem SL Vaccine; 1991 Mar; 9(3):201-3. PubMed ID: 2042392 [TBL] [Abstract][Full Text] [Related]
14. Aluminium adjuvants in vaccines - A way to modulate the immune response. Danielsson R; Eriksson H Semin Cell Dev Biol; 2021 Jul; 115():3-9. PubMed ID: 33423930 [TBL] [Abstract][Full Text] [Related]